Carrier erythrocyte entrapped thymidine phosphorylase therapy for MNGIE.
Moran
N F
NF
Neurology, Kent & Canterbury Hospital, Ethelbert Road, Canterbury, CT1 3NG, UK. nfm10@aol.com
Bain
M D
MD
Muqit
M M K
MM
Bax
B E
BE
D000328:Adult; D003857:Deoxyuridine / Q000652:urine; D016503:Drug Delivery Systems; D017707:Erythrocyte Transfusion / Q000379:methods*; D004912:Erythrocytes / Q000201:enzymology; D017809:Fatal Outcome; D005260:Female; D005767:Gastrointestinal Diseases / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006801:Humans; D008107:Liver Diseases / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology; D028361:Mitochondrial Diseases / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology; D009154:Mutation / Q000235:genetics; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology; D011014:Pneumonia / Q000150:complications; D013577:Syndrome; D013936:Thymidine / Q000652:urine; D013939:Thymidine Phosphorylase / Q000235:genetics / Q000627:therapeutic use*; D017211:Treatment Failure
D013939:Thymidine Phosphorylase; D013936:Thymidine; D003857:Deoxyuridine